Tonix Pharmaceuticals (TNXP) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update
March 4, 2016 7:00 AM ESTNEW YORK, March 04, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced financial results for the fourth quarter and full year ended December 31, 2015.
Tonix made tremendous progress over the course of 2015 on the clinical, regulatory and operational fronts. We remain very focused on progressing our... More
Tonix Pharmaceuticals to Present at Two Investor Conferences in March 2016
March 3, 2016 7:00 AM ESTNEW YORK, March 03, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix, will present a corporate update twice this month, at conferences sponsored by Cowen & Co. and BioCentury.
Event: 36th... More
